Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 204 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

204 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 204 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

204 programs

Clinical programs

Page 1 of 5

  1. 01API2024

    Lacuna Pharma Pty Ltd

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  2. 01INDA2024

    Lacuna Pharma Pty Ltd

    Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

    phase 1 other active

    1 trial

  3. 02API2024

    Lacuna Pharma Pty Ltd

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  4. 039(C/a)MD23341

    Lacuna Pharma Pty Ltd

    Intended indication: Major Depressive Disorders with and without anxiety, Healthy volunteers, therapeutic indication not studied

    phase 1 other active

    1 trial

  5. 0439-24

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 1 other active

    1 trial

  6. 1028/25

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  7. 1046/25

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  8. 1048/25

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  9. 1053/25

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  10. 131I-TLX-101-002

    Lacuna Pharma Pty Ltd

    Glioblastoma multiforme (GBM)

    phase 1 other active

    1 trial

  11. 14-XC-CL

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

  12. 2025-GMF-1

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  13. 2025-GMF-1

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  14. 67896062PAH1011

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  15. 845900241/0147/1

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a bioavailability study in healthy subjects)

    phase 1 other active

    1 trial

  16. 987/24

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a bioavailability study in healthy subjects).

    phase 1 other active

    1 trial

  17. 988/24

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a bioavailability study in healthy subjects).

    phase 1 other active

    1 trial

  18. A Clinical Study to Compare the Impact of Mul...

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  19. A randomised for Depression, Cognitive dysfuncti…

    Lacuna Pharma Pty Ltd

    Depression, Cognitive dysfunction, Alzheimer’s disease

    phase 1 other active

    1 trial

  20. A randomized double-blind placebo-controlled... for Circulatory shock

    Lacuna Pharma Pty Ltd

    Circulatory shock

    phase 1 other active

    1 trial

  21. A randomized for healthy male subjects

    Lacuna Pharma Pty Ltd

    healthy male subjects

    phase 1 other active

    1 trial

  22. A single-dose for hypertension

    Lacuna Pharma Pty Ltd

    hypertension

    phase 1 other active

    1 trial

  23. A148_01PK2408

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  24. A160_01AD2502

    Lacuna Pharma Pty Ltd

    Phase I study in healthy participants. Intended indication: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  25. ACE-LY-106

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 1 other active

    1 trial

  26. ADO-01-24

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  27. ALN-SNCA-PD-2482

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  28. ALY688ER-101

    Lacuna Pharma Pty Ltd

    NASH

    phase 1 other active

    1 trial

  29. AMO-02-MD-1-001

    Lacuna Pharma Pty Ltd

    Hepatic impairment, Healthy subjects

    phase 1 other active

    1 trial

  30. AN OPEN-LABEL for Intramuscular administration of…

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  31. APC148-001

    Lacuna Pharma Pty Ltd

    Urinary tract infections (UTIs)/complicated UTI (cUTI)

    phase 1 other active

    1 trial

  32. ARV-BA-001

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial

  33. An Open-Label for Solid tumors and ovarian cancer

    Lacuna Pharma Pty Ltd

    Solid tumors and ovarian cancer

    phase 1 other active

    1 trial

  34. An open-label for inteneded for treatment of - ac…

    Lacuna Pharma Pty Ltd

    inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

    phase 1 other active

    1 trial

  35. BAL2420-CP-101

    Lacuna Pharma Pty Ltd

    Severe infections caused by Gram-negative bacteria

    phase 1 other active

    1 trial

  36. BLCL-CAB-PIL01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  37. BLCL-LEN-EU-01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  38. BLCL-LEN-FDA-01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  39. BLCL-LEN-FDA-02

    Lacuna Pharma Pty Ltd

    No medical condition

    phase 1 other active

    1 trial

  40. BLCL-LEN-FDA-03

    Lacuna Pharma Pty Ltd

    No medical condition

    phase 1 other active

    1 trial

  41. BLCL-LIS-CAN-01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  42. BLCL-LIS-EU-01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  43. BLCL-LIS-EU-02

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  44. BLCL-LIS-EU-03

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  45. BLCL-LIS-PIL01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  46. BLCL-NIL-FDA-02

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  47. BLCL-RUX-EU-01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

  48. BLCL-RUX-FDA-01

    Lacuna Pharma Pty Ltd

    No medical condition.

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

204 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.